Marché du diagnostic du cancer de l’ovaire au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et perspectives du marché du diagnostic du cancer de l'ovaire au Moyen-Orient et en Afrique 

Le cancer de l'ovaire est un type de cancer qui se forme dans les tissus de l'ovaire (l'une des deux glandes reproductrices féminines dans lesquelles se forment les ovules). La plupart des cancers de l'ovaire sont soit des cancers épithéliaux de l'ovaire (un cancer qui commence dans les cellules à la surface de l'ovaire) soit des tumeurs germinales malignes (un cancer qui commence dans les ovules). Les tests et procédures utilisés pour diagnostiquer le cancer de l'ovaire comprennent l'examen pelvien, les tests d'imagerie, les analyses sanguines, la chirurgie, entre autres. Lors d'un examen pelvien, le médecin insère des doigts gantés dans le vagin et appuie simultanément une main sur l'abdomen afin de sentir (palper) les organes pelviens.

Le marché du diagnostic du cancer de l'ovaire au Moyen-Orient et en Afrique devrait croître au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,1 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 438,80 millions USD d'ici 2030 contre 274,52 millions USD en 2022.

Définition du marché du diagnostic du cancer de l'ovaire au Moyen-Orient et en Afrique

Ovarian cancer is most common in women between the ages of 50 and 79. It is becoming more prevalent as the world's geriatric population grows and there is a greater emphasis on early detection and treatment, which is expected to accelerate ovarian cancer diagnostic market development. Increasing government investment in raising awareness about early cancer detection as well as increasing health-care spending would also propel business growth. Obesity appears to play a significant role in the development of ovarian cancer. Other lifestyle choices that can raise the risk include smoking, drinking, and not having children. Since ovarian cancer is not easily detectable, women who are at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.

The Middle East and Africa ovarian cancer diagnostic market is growing in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in ovarian cancer diagnostics and development is further boosting the market growth. However, difficulties in ovarian cancer screening techniques might hamper the growth of the Middle East and Africa ovarian cancer diagnostic market in the forecast period.

Middle East and Africa Ovarian Cancer Diagnostics Market  Dynamics

Drivers

• Growing Ovarian Cancer Awareness

Growing ovarian cancer awareness has led to an increased demand for timely cancer detection, leading to market growth.

Ovarian cancer is one of the major causes of rising mortality rates among female populations worldwide, which is fuelling market growth over the next five years. Cancer in the ovaries and cysts is becoming more common due to various factors such as environmental factors and genetic mutations.

Ovarian cancer is a type of cancer that affects women’s egg-producing organs, the ovaries. Ovarian cancer is difficult to diagnose because the symptoms are vague and are often detected only after cancer has spread through the stomach and pelvis, making it difficult to cure.

As a result, improved diagnostic processes and techniques are required to determine the cancer stage to treat. Furthermore, the rising mortality rate from ovarian cancer is concerning, emphasizing the importance of early detection so that treatment can be provided.

Due to an increase in awareness about ovarian cancer, it is expected to act as a driving factor for market growth.

• Improved Diagnostic Processes and Techniques

Screening tests and exams are used to detect a disease, such as cancer, in people who do not have any symptoms. There has been a lot of research to develop a screening test for ovarian cancer, but there has not been much success so far. The two tests used most often (in addition to a complete pelvic exam) to screen for ovarian cancer are Transvaginal Ultrasound (TVUS) and the CA-125 blood test.

TVUS is a test that uses sound waves to look at the uterus, fallopian tubes, and ovaries by putting an ultrasound wand into the vagina. It can help find a mass (tumor) in the ovary, but it cannot actually tell if a mass is cancer or benign. When it is used for screening, most of the masses found are not cancer.

The CA-125 blood test measures the amount of a protein called CA-125 in the blood. Many women with ovarian cancer have high levels of CA-125. This test can be useful as a tumor marker to help guide treatment in women known to have ovarian cancer because a high level often goes down if treatment is working. But checking CA-125 levels is not as useful as a screening test for ovarian cancer.

Thus, due to the increase in improved diagnostic processes and techniques, it is expected to act as a driving factor for market growth.

RESTRAINTS

High Cost of Diagnosis

Worldwide, the costs of cancer treatment have increased. Health industries are facing several challenges like medical costs for cancer care. The cost of cancer care in 2010 was USD 124.60 billion which was projected to increase to USD 173.00 billion by 2020 with cancer drug prices and acute hospital care as the main drivers. Hence, the increased cost of diagnostic agents production is hampering the market growth.

Lack of Skilled Professionals

Healthcare professionals involved in the diagnostic process have an obligation and ethical responsibility to employ clinical reasoning skills, evaluate, and manage a patient's medical problems. When a diagnosis is accurate and made in a timely manner, a patient has the best opportunity for a positive health outcome because clinical decision-making will be tailored to a correct understanding of the patient's health problem. The lack of skilled professionals may hinder the recovery process of the patient and thus, may hamper the market growth.

OPPORTUNITIES

Increasing Healthcare Expenditure for Cancer Diagnosis and Treatment

Across the globe, R&D activities are escalating owing to public health expenditure with economic performances whereas, the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to upsurge the demand for ovarian cancer diagnostics.

Increasing healthcare expenditure for cancer treatment also helps patients to take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their own care), government expenditure, and sources including health insurance and activities by Non-Governmental Organizations (NGOs). Due to this increasing healthcare expenditure for cancer treatment, it acts as an opportunity for market growth.

CHALLENGES

Strict Regulations and Standards for the Approval and Commercialization of Cancer Diagnostic Products                      

The stringent regulations for commercialization of any product in the market are proving to be a big challenge for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has its own regulations and has a different body for regulatory procedures.

In the U.S., manufacturers require marketing authorization approval for IVD products for human use. The product must be labeled in accordance with labeling regulations. Establishments involved in the production and distribution of medical devices intended for commercial distribution in the U.S. are required to register with the FDA. Registration provides the FDA with the location of medical device manufacturing facilities and importers. Registration of an establishment is not an approval of the establishment or its devices by the FDA, that is, it does not provide FDA authorization to market the device. Unless exempted, premarketing authorization is required before a device can be placed into commercial distribution in the U.S.

The regulatory requirement for approvals of marketing as well as the declaration of conformity and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval on the products, manufacturers are not able to launch their product in the market and for this reason, strict regulations and standards for the approval and commercialization of cancer diagnostic products act as a restraining factor for market growth.

Recent Developments

• In November 2022, Myriad genetics Inc. announced that it has acquired Gateway Genomics, LLC, The acquisition strengthens Myriad Genetics’ portfolio of Women’s Health products, expanding access to personalized genetic tests during the reproductive stage of a women’s life and beyond. With SneakPeek, Myriad now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for all ancestries, this will help the company to increase their revenue.
• In October 2022, Quest Diagnostics announced the new phase of collaboration with Decode health, in the starting phase of collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets for different types of cancers (breast, prostate and ovarian cancer). This collaboration helps the company to find innovative paths in the field of R&D and increases the Middle East and Africa presence of the company.

Middle East and Africa Ovarian Cancer Diagnostics Market Scope

Middle East and Africa ovarian cancer diagnostics market is segmented into product type, procedure type, cancer type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Instruments
• Kits and Reagents

On the basis of product type, the Middle East and Africa ovarian cancer diagnostics market is segmented into instruments and kits and reagents.

Procedure Type

• Blood Markers Testing
• Medical Imaging Test
• Biopsy Tests
• Genetic Testing

On the basis of procedure type, the Middle East and Africa ovarian cancer diagnostics market is segmented into blood markers testing, medical imaging test, biopsy tests and genetic testing

Cancer Type

• Epithelial Tumor
• Germ Cell
• Stromal Cell Tumor

On the basis of cancer type, the Middle East and Africa ovarian cancer diagnostics market is segmented into epithelial tumor, germ cell and stromal cell tumor

End User

• Cancer Diagnostic Centers
• Hospital Laboratories
• Research Institutes
• Others

On the basis of end user, the Middle East and Africa ovarian cancer diagnostics market is segmented into cancer diagnostic centers, hospital laboratories, research institutes and others

Middle East and Africa Ovarian Cancer Diagnostics Market Regional Analysis/Insights       

The Middle East and Africa ovarian cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, procedure type, cancer type and end user, as referenced above.

The countries covered in this market report are South Africa, Saudi Arabia, U.A.E, Egypt, Israel and Rest of Middle East and Africa.

South Africa is dominating the Middle East and Africa ovarian cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Ovarian Cancer Diagnostics Market Share Analysis

Le paysage concurrentiel du marché du diagnostic du cancer de l'ovaire fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du diagnostic du cancer de l'ovaire.

Certains des principaux acteurs opérant sur le marché du diagnostic du cancer de l'ovaire au Moyen-Orient et en Afrique sont F. Hoffmann-la roche ltd, Tosoh india pvt. Ltd., Luminex corporation, Quest diagnostics incorporated, Thermo fisher scientific Inc., Ngenebio, Abbott, Siemens healthcare private limited, Myriad genetics Inc., Bio-rad laboratories, Inc., Abcam plc., Monobind Inc., Mp biomedicals, Boster biological technology, Genway biotech et Lifespan biosciences, Inc entre autres.

SKU-69478